This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bogazzi, F. Articles by Martino, E. Search for Related Content PubMed PubMed Citation Articles by Bogazzi, F. Articles by Martino, E.

Treatment with Lithium Prevents Serum Thyroid Hormone Increase after Thionamide Withdrawal and Radioiodine Therapy in Patients with Graves’ Disease

Department of Endocrinology and Metabolism (F.B., A.C., S.B., F.L., A.P., E.M.), University of Pisa, 56124 Pisa; Department of Endocrinology and Metabolism (L.B.), University of Insubria, 21100 Varese; Service of Radiation Safety (C.T., F.D.M.), S. Chiara Hospital, 56100 Pisa; and Department of Epidemiology and Biostatistics (G.R.), Institute of Clinical Physiology, National Research Council (CNR), 56100 Pisa, Italy

Address all correspondence and requests for reprints to: Fausto Bogazzi, M.D., Dipartimento di Endocrinologia e Metabolismo, Università di Pisa, Ospedale di Cisanello, Via Paradisa, 2, 56124 Pisa, Italy. E-mail: f.bogazzi{at}endoc.med.unipi.it or fbogazzi{at}hotmail.com.

Abstract

Serum thyroid hormone concentrations increase after radioiodine (RAI) therapy for Graves’ disease. This phenomenon has been ascribed to either antithyroid drug withdrawal before RAI therapy or release of preformed thyroid hormones into the bloodstream from the RAI-damaged thyroid. Lithium blocks the release of iodine and thyroid hormones from the thyroid, thus enhancing the effectiveness of RAI therapy. Changes in serum-free thyroxine (FT4) and triiodothyronine (FT3) levels after methimazole (MMI) discontinuation and RAI therapy were evaluated in a prospective, randomized, control study of 36 patients with Graves’ disease. After a 3- to 4-month course of MMI, patients were assigned to one of three groups: G1 (RAI alone); G2 (RAI plus lithium for 6 d starting on the day of RAI therapy); or G3 (RAI plus lithium for 19 d starting on the day of MMI withdrawal). G1-G2 patients had an increase in serum FT4 and FT3 levels from 13.5 ± 6.5 to 19.8 ± 9.2 pmol/liter and 5.0 ± 2.0 to 8.0 ± 4.8 pmol/liter, respectively (P < 0.0001), 2–5 d after MMI withdrawal, but G3 patients showed no changes. In the 30 d after RAI therapy, mean serum FT4 values increased in G1 patients (P = 0.02), peaking at 3–7 d (P < 0.05) but not in G2 and G3 patients. Serum FT3 levels decreased in G1, G2, and G3 (P = 0.03, P = 0.001, P = 0.02, respectively). Hyperthyroidism was cured in 8 of 12 G1 patients, 11 of 12 G2 patients, and 11 of 12 G3 patients (P = 0.31). Control of hyperthyroidism was prompter in G2 (P = 0.08) and G3 (P < 0.05) than in G1 patients. Patients in the three groups received a similar dose of RAI, but the committed radiation to the thyroid was higher in G3 (563 ± 174 Gray) and G2 (588 ± 347 Gray) than in G1 (429 ± 204 Gray) (P < 0.03). In conclusion, the results of the present study demonstrate that: 1) MMI withdrawal is associated with a slight rise in serum thyroid hormone levels; 2) a further increase occurs after RAI therapy; 3) changes in serum thyroid hormone concentrations are prevented by lithium; and 4) the increased effectiveness of RAI therapy in lithium-treated patients is related to the increased RAI retention in the thyroid gland. Accordingly, a short course of lithium therapy can be considered a useful adjunct to RAI therapy to obtain a prompter control of thyrotoxicosis and avoid its transient exacerbation because of MMI withdrawal and RAI administration.

This article has been cited by other articles:

				L. Bartalena, M. L Tanda, E. Piantanida, and A. Lai Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism Eur. J. Endocrinol., July 1, 2005; 153(1): 13 - 14. [Full Text] [PDF]

				L. Bartalena, F. Bogazzi, A. Pinchera, and E. Martino Treatment with Thionamides before Radioiodine Therapy for Hyperthyroidism: Yes or No? J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1256 - 1256. [Full Text] [PDF]

				G Birrell and T Cheetham Juvenile thyrotoxicosis; can we do better? Arch. Dis. Child., August 1, 2004; 89(8): 745 - 750. [Abstract] [Full Text] [PDF]

				D. S. Cooper Antithyroid Drugs in the Management of Patients with Graves' Disease: An Evidence-Based Approach to Therapeutic Controversies J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3474 - 3481. [Full Text] [PDF]